Publication date: 24/01/2018
UgenTec, an innovative European medical device software company that develops artificially intelligent PCR interpretation software, announced today a partnership agreement with MDxHealth, a multinational healthcare company that uses molecular diagnostics to personalize urological cancer diagnosis and treatment.
In the partnership, UgenTec will develop artificially intelligent software to support the interpretation of molecular test results for SelectMDx & ConfirmMDx for Prostate Cancer tests.
The SelectMDx test is a liquid biopsy diagnostic test that helps identify patients at increased risk for clinical significant prostate cancer. ConfirmMDx is a tissue biopsy test to forgo an unnecessary repeat biopsy procedure.
“This automation step will help us to handle the increasing volumes and QC requirements in both our certified laboratories in Europe and the US. It will also provide our SelectMDx IVD customers with an advanced software they can use support and standardize drafting of result reports,” said Dr. Jan Groen, CEO at MDxHealth.
“We’re proud to work with one of the market leaders in urological cancer diagnostics,” said Dr. Tom Martens, Managing Director at UgenTec, “we will use our extensive expertise on PCR interpretation challenges to streamline and optimize MDxHealth’s testing procedures for these two products”.
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The increased adoption of our ConfirmMDx® for Prostate Cancer testing solution within the U.S. urology community has established MDxHealth as a market leader in the important and growing field of cancer epigenetics.